| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
5-Hydroxydecanoic acid targets ATP-sensitive potassium (KATP) channels, acting as a selective antagonist. It blocks KATP channels only during ischemia by competing with the ATP binding site. It does not affect pancreatic KATP channels, indicating some selectivity. It is also a substrate for mitochondrial outer membrane acyl-CoA synthetase.
|
|---|---|
| ln Vitro |
5-Hydroxydecanoic acid is a selective KATP channel blocker with an IC50 of approximately 30 μM. It blocks KATP channels only during ischemia and does not affect pancreatic KATP channels. It is a substrate for mitochondrial outer membrane acyl-CoA synthetase and has antioxidant activity. Its activity has been confirmed in various electrophysiological and biochemical assays.
|
| ln Vivo |
5-Hydroxydecanoic acid blocks the postischemic effects of the potassium channel activator cromakalim. Its selective KATP channel blocking activity during ischemia suggests potential applications in protecting against ischemic injury. However, specific in vivo efficacy data is limited. It is primarily used as a research tool.
|
| Enzyme Assay |
The primary in vitro assay for 5-Hydroxydecanoic acid is electrophysiological recording using the patch-clamp technique. KATP channels are expressed in cells or studied in native tissues, and the compound's ability to block KATP channel currents is measured. Its IC50 of approximately 30 μM is determined from dose-response curves.
|
| Cell Assay |
In vitro cellular experiments for 5-Hydroxydecanoic acid involve treating cells expressing KATP channels with the compound and measuring its effects on channel activity. The inhibition of KATP channel currents is measured using patch-clamp techniques. Its effects on mitochondrial function and oxidative stress can be assessed in relevant cell models.
|
| Animal Protocol |
In vivo animal experiments for 5-Hydroxydecanoic acid have been conducted to assess its effects on ischemic injury. The compound is administered to animal models of ischemia, and its effects on tissue damage and recovery are assessed. Its ability to block the effects of KATP channel openers has also been evaluated.
|
| ADME/Pharmacokinetics |
5-Hydroxydecanoic acid has a molecular weight of 188.26 g/mol and a molecular formula of C10H20O3. It is a medium-chain fatty acid. It is typically used as a research reagent and is stored at -20°C for long-term stability. Its purity is typically ≥98%.
|
| Toxicity/Toxicokinetics |
5-Hydroxydecanoic acid is a research compound that is not intended for human use. Its toxicological profile is not extensively characterized in the available literature. As with all research chemicals, standard safety precautions should be followed when handling. Its safety would need to be established for therapeutic applications.
|
| References | |
| Additional Infomation |
5-Hydroxydecanoic acid is a medium-chain fatty acid.
5-Hydroxydecanoic acid (5-HD) is a medium-chain fatty acid derivative that functions as a selective ATP-sensitive potassium (KATP) channel antagonist. It blocks KATP channels only during ischemia and does not affect pancreatic KATP channels. The compound is used as a research tool to study KATP channel function and ischemic injury and is available from various chemical suppliers for research purposes. |
| Molecular Formula |
C10H20O3
|
|---|---|
| Molecular Weight |
188.27
|
| Exact Mass |
188.141
|
| CAS # |
624-00-0
|
| PubChem CID |
1825
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.182
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
13
|
| Complexity |
134
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCC(O)CCCC(O)=O
|
| InChi Key |
LMHJFKYQYDSOQO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H20O3/c1-2-3-4-6-9(11)7-5-8-10(12)13/h9,11H,2-8H2,1H3,(H,12,13)
|
| Chemical Name |
5-hydroxydecanoic acid
|
| Synonyms |
Sodium 5-hydroxydecanoate; 5-Hydroxydecanoate; 5-Hydroxydecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3115 mL | 26.5576 mL | 53.1152 mL | |
| 5 mM | 1.0623 mL | 5.3115 mL | 10.6230 mL | |
| 10 mM | 0.5312 mL | 2.6558 mL | 5.3115 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
